vs

Side-by-side financial comparison of Brown–Forman (BF.B) and MEDIFAST INC (MED). Click either name above to swap in a different company.

Brown–Forman is the larger business by last-quarter revenue ($1.0B vs $75.1M, roughly 13.8× MEDIFAST INC). On growth, Brown–Forman posted the faster year-over-year revenue change (-5.4% vs -36.9%). Brown–Forman produced more free cash flow last quarter ($107.0M vs $-6.6M). Over the past eight quarters, Brown–Forman's revenue compounded faster (-1.6% CAGR vs -34.4%).

Brown-Forman Corporation is an American family-controlled publicly traded company, one of the largest in the spirits and wine business. Based in Louisville, Kentucky, it manufactures several very well known brands throughout the world, including Jack Daniel's, Old Forester, Woodford Reserve, GlenDronach, BenRiach, Glenglassaugh, Herradura, Korbel, and Chambord. Brown-Forman formerly owned Southern Comfort and Tuaca before selling them off in 2016.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

BF.B vs MED — Head-to-Head

Bigger by revenue
BF.B
BF.B
13.8× larger
BF.B
$1.0B
$75.1M
MED
Growing faster (revenue YoY)
BF.B
BF.B
+31.5% gap
BF.B
-5.4%
-36.9%
MED
More free cash flow
BF.B
BF.B
$113.6M more FCF
BF.B
$107.0M
$-6.6M
MED
Faster 2-yr revenue CAGR
BF.B
BF.B
Annualised
BF.B
-1.6%
-34.4%
MED

Income Statement — Q2 2026 vs Q4 2025

Metric
BF.B
BF.B
MED
MED
Revenue
$1.0B
$75.1M
Net Profit
$224.0M
Gross Margin
59.4%
69.4%
Operating Margin
29.4%
-10.4%
Net Margin
21.6%
Revenue YoY
-5.4%
-36.9%
Net Profit YoY
-13.2%
EPS (diluted)
$0.47
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BF.B
BF.B
MED
MED
Q4 25
$1.0B
$75.1M
Q3 25
$924.0M
$89.4M
Q2 25
$894.0M
$105.6M
Q1 25
$1.0B
$115.7M
Q4 24
$1.1B
$119.0M
Q3 24
$951.0M
$140.2M
Q2 24
$964.0M
$168.6M
Q1 24
$1.1B
$174.7M
Net Profit
BF.B
BF.B
MED
MED
Q4 25
$224.0M
Q3 25
$170.0M
$-2.3M
Q2 25
$146.0M
$2.5M
Q1 25
$270.0M
$-772.0K
Q4 24
$258.0M
Q3 24
$195.0M
$1.1M
Q2 24
$266.0M
$-8.2M
Q1 24
$285.0M
$8.3M
Gross Margin
BF.B
BF.B
MED
MED
Q4 25
59.4%
69.4%
Q3 25
59.7%
69.5%
Q2 25
57.4%
72.6%
Q1 25
59.8%
72.8%
Q4 24
59.0%
74.1%
Q3 24
59.4%
75.4%
Q2 24
59.0%
73.2%
Q1 24
59.4%
72.8%
Operating Margin
BF.B
BF.B
MED
MED
Q4 25
29.4%
-10.4%
Q3 25
28.1%
-4.6%
Q2 25
22.9%
-1.0%
Q1 25
27.1%
-1.1%
Q4 24
31.1%
0.6%
Q3 24
29.5%
1.5%
Q2 24
38.9%
-4.7%
Q1 24
34.9%
4.5%
Net Margin
BF.B
BF.B
MED
MED
Q4 25
21.6%
Q3 25
18.4%
-2.5%
Q2 25
16.3%
2.3%
Q1 25
26.1%
-0.7%
Q4 24
23.6%
Q3 24
20.5%
0.8%
Q2 24
27.6%
-4.8%
Q1 24
26.7%
4.8%
EPS (diluted)
BF.B
BF.B
MED
MED
Q4 25
$0.47
$-1.64
Q3 25
$0.36
$-0.21
Q2 25
$0.31
$0.22
Q1 25
$0.57
$-0.07
Q4 24
$0.55
$0.08
Q3 24
$0.41
$0.10
Q2 24
$0.56
$-0.75
Q1 24
$0.60
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BF.B
BF.B
MED
MED
Cash + ST InvestmentsLiquidity on hand
$319.0M
$167.3M
Total DebtLower is stronger
$2.4B
Stockholders' EquityBook value
$4.1B
$198.9M
Total Assets
$8.2B
$248.0M
Debt / EquityLower = less leverage
0.59×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BF.B
BF.B
MED
MED
Q4 25
$319.0M
$167.3M
Q3 25
$471.0M
$173.5M
Q2 25
$444.0M
$162.7M
Q1 25
$599.0M
$164.6M
Q4 24
$416.0M
$162.3M
Q3 24
$416.0M
$170.0M
Q2 24
$446.0M
$163.5M
Q1 24
$589.0M
$156.4M
Total Debt
BF.B
BF.B
MED
MED
Q4 25
$2.4B
Q3 25
$2.4B
Q2 25
$2.4B
Q1 25
$2.7B
Q4 24
$2.7B
Q3 24
$2.7B
Q2 24
$2.7B
Q1 24
$2.7B
Stockholders' Equity
BF.B
BF.B
MED
MED
Q4 25
$4.1B
$198.9M
Q3 25
$4.0B
$214.7M
Q2 25
$4.0B
$216.0M
Q1 25
$3.8B
$211.0M
Q4 24
$3.7B
$210.1M
Q3 24
$3.5B
$207.3M
Q2 24
$3.5B
$205.3M
Q1 24
$3.2B
$211.0M
Total Assets
BF.B
BF.B
MED
MED
Q4 25
$8.2B
$248.0M
Q3 25
$8.2B
$268.2M
Q2 25
$8.1B
$269.3M
Q1 25
$8.1B
$280.0M
Q4 24
$8.3B
$284.2M
Q3 24
$8.2B
$291.2M
Q2 24
$8.2B
$293.5M
Q1 24
$8.2B
$302.8M
Debt / Equity
BF.B
BF.B
MED
MED
Q4 25
0.59×
Q3 25
0.61×
Q2 25
0.61×
Q1 25
0.70×
Q4 24
0.73×
Q3 24
0.77×
Q2 24
0.76×
Q1 24
0.83×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BF.B
BF.B
MED
MED
Operating Cash FlowLast quarter
$132.0M
$-5.3M
Free Cash FlowOCF − Capex
$107.0M
$-6.6M
FCF MarginFCF / Revenue
10.3%
-8.8%
Capex IntensityCapex / Revenue
2.4%
1.8%
Cash ConversionOCF / Net Profit
0.59×
TTM Free Cash FlowTrailing 4 quarters
$610.0M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BF.B
BF.B
MED
MED
Q4 25
$132.0M
$-5.3M
Q3 25
$160.0M
$12.1M
Q2 25
$152.0M
$-3.4M
Q1 25
$317.0M
$3.4M
Q4 24
$112.0M
$-4.9M
Q3 24
$17.0M
$9.1M
Q2 24
$285.0M
$13.1M
Q1 24
$265.0M
$7.3M
Free Cash Flow
BF.B
BF.B
MED
MED
Q4 25
$107.0M
$-6.6M
Q3 25
$129.0M
$10.8M
Q2 25
$102.0M
$-4.8M
Q1 25
$272.0M
$1.9M
Q4 24
$81.0M
$-7.2M
Q3 24
$-24.0M
$7.7M
Q2 24
$205.0M
$11.1M
Q1 24
$196.0M
$5.4M
FCF Margin
BF.B
BF.B
MED
MED
Q4 25
10.3%
-8.8%
Q3 25
14.0%
12.0%
Q2 25
11.4%
-4.5%
Q1 25
26.3%
1.6%
Q4 24
7.4%
-6.1%
Q3 24
-2.5%
5.5%
Q2 24
21.3%
6.6%
Q1 24
18.3%
3.1%
Capex Intensity
BF.B
BF.B
MED
MED
Q4 25
2.4%
1.8%
Q3 25
3.4%
1.5%
Q2 25
5.6%
1.3%
Q1 25
4.3%
1.3%
Q4 24
2.8%
1.9%
Q3 24
4.3%
1.0%
Q2 24
8.3%
1.1%
Q1 24
6.5%
1.1%
Cash Conversion
BF.B
BF.B
MED
MED
Q4 25
0.59×
Q3 25
0.94×
Q2 25
1.04×
-1.36×
Q1 25
1.17×
Q4 24
0.43×
Q3 24
0.09×
8.04×
Q2 24
1.07×
Q1 24
0.93×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BF.B
BF.B

Whiskey$771.0M74%
Ready To Drink$138.0M13%
Tequila$67.0M6%
Restofportfolio$52.0M5%
Nonbrandedandbulk$8.0M1%

MED
MED

Segment breakdown not available.

Related Comparisons